Attention Deficit Disorder With Hyperactivity Clinical Trial
Official title:
Investigating the Neuro-Cognitive Underpinnings of the Emotional Dysfunction Linked to Childhood Behavioral Disturbance
Purpose:
This study will examine brain activity in children age 10-18 with disruptive behavior
problems, including conduct disorder (CD), oppositional defiant disorder (ODD), and attention
deficit hyperactivity disorder (ADHD), compared with children without behavioral problems.
Our goal is to examine differences in how emotions, social situations, and problem-solving
situations are processed in the brain across these groups of children.
OBJECTIVE:
The goal of this protocol is to investigate the neuro-cognitive underpinnings of the
emotional dysfunction linked to childhood behavioral disturbance; in particular, Conduct
Disorder with elevated callous-unemotional (CU) traits (CD+CU), Conduct Disorder with non
elevated CU traits (CD-CU), but also ADHD. The functional hypotheses that we are testing with
both neuro-cognitive and neuro-imaging paradigms are that: (1) CD+CU, but not ADHD, is
associated with dysfunction in the formation and operational use of stimulus-punishment and,
to a lesser extent, stimulus-reward association information; (2) CD-CU is associated with
heightened threat sensitivity and impairment in executive systems involved in emotional
regulation; and (3) that ADHD and CD-CU, is associated with impairment in executive systems
related to the representation and execution of task demands.
STUDY POPULATION:
160 children with Conduct Disorder (CD) and high CU traits (the CD+CU group); 160 children
with CD and low CU traits (the CD-CU group); 160 children with ADHD; and 160 healthy
volunteer children. All children will be between the ages of 10 and 17. Both males and
females will be enrolled.
DESIGN:
The current study will have two phases: i) neuropsychological assessment and training in an
MRI simulator (up to 4 hours); ii) The MRI scanning session (up to 2 hours, no more than 90
minutes in scanner). Participants, if they are willing, may be invited to participate in more
than one scanning session (up to a maximum of 3 120 minute sessions) or neuro-cognitive
testing session.
OUTCOME MEASURES:
Behaviorally, we predict that children with CD+CU and children with CD-CU will present with
impairment on tasks that involve either the formation or operational use of particular
stimulus-punishment associations (e.g., the subjective value learning task and emotional
interrupt task). However, the nature of this impairment with be qualitatively different. For
example, we predict that youth with CD+CU will show reduced interference by emotional
distracters on the emotional interrupt task but that youth with CD-CU will show decreased
interference. In contrast, we predict that children with ADHD, but no CD, will show no
behavioral impairment on such tasks. However, we predict that children with ADHD and children
with CD-CU will present with impairments on executive function tasks (e.g., the Number Stroop
paradigm). In contrast, we predict that children with CD+CU will show no impairment on these
tasks. At the anatomical level, we anticipate reduced activation of emotional related systems
in children with CD+CU, but increased activation in children with CD-CU, during emotional
impact tasks (in particular, reduced activation of the amygdala, regions of orbitofrontal
cortex and anterior cingulate). We anticipate that the neural response of children with ADHD
during these tasks will be less anomalous. We anticipate that the neural response of children
with ADHD and children with CD-CU during the performance of response control tasks to be
anomalous (with considerable greater recruitment of anterior and posterior compensatory
systems).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00202605 -
Safety and Efficacy of SPD465 in Adults With ADHD
|
Phase 2 | |
Not yet recruiting |
NCT02677519 -
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
|
Phase 4 | |
Completed |
NCT02730572 -
Concerta (Methylphenidate) -To-Generic Switch Study
|
N/A | |
Completed |
NCT01681082 -
Psychological Effects of Tai Chi Training
|
N/A | |
Active, not recruiting |
NCT01330693 -
Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy
|
Phase 3 | |
Completed |
NCT00830700 -
Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study
|
N/A | |
Completed |
NCT00626236 -
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
|
Phase 2 | |
Completed |
NCT01012622 -
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
|
Phase 4 | |
Completed |
NCT00598182 -
Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study
|
N/A | |
Completed |
NCT00381407 -
Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT00178503 -
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
|
Phase 2/Phase 3 | |
Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 | |
Completed |
NCT00118911 -
Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT00557011 -
NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD
|
Phase 2 | |
Completed |
NCT00218322 -
Effectiveness of ATMX in Treating Adolescents With ADHD and SUD
|
Phase 4 | |
Completed |
NCT00071656 -
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I
|
N/A | |
Active, not recruiting |
NCT00057668 -
Preventing Behavior Problems in Children With ADHD
|
Phase 2 | |
Completed |
NCT00050622 -
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT00050050 -
Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder
|
Phase 1 | |
Completed |
NCT00031395 -
Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children
|
Phase 3 |